| human | Q5 |
| P6178 | Dimensions author ID | 01013123234.18 |
| P496 | ORCID iD | 0000-0002-5511-1686 |
| P1153 | Scopus author ID | 7003304472 |
| P108 | employer | Harvard Medical School | Q49121 |
| Boston Children's Hospital | Q1000479 | ||
| Memorial Sloan Kettering Cancer Center | Q1808012 | ||
| New York Blood Center | Q7013074 | ||
| P735 | given name | Andrei | Q19850904 |
| Andrei | Q19850904 | ||
| P106 | occupation | researcher | Q1650915 |
| Q36286764 | A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence |
| Q92508672 | A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies |
| Q34918857 | AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. |
| Q48280304 | Cancer. Can one cell influence cancer heterogeneity? |
| Q33761368 | Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. |
| Q30355347 | DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling |
| Q35920110 | Gene expression profiling of leukemia stem cells. |
| Q36991857 | H3K79 methylation profiles define murine and human MLL-AF4 leukemias |
| Q35789992 | Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. |
| Q40182756 | Jedi--a novel transmembrane protein expressed in early hematopoietic cells. |
| Q38830247 | Loss of BAP1 function leads to EZH2-dependent transformation |
| Q29615368 | MLL translocations, histone modifications and leukaemia stem-cell development |
| Q35898171 | MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. |
| Q28267938 | Mediator kinase inhibition further activates super-enhancer-associated genes in AML |
| Q36984373 | Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins |
| Q37676855 | Pathprinting: An integrative approach to understand the functional basis of disease |
| Q85542120 | Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia |
| Q40252270 | Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. |
| Q53368106 | Transformation from committed progenitor to leukemia stem cells. |
Search more.